Positive phase 3 results for AstraZeneca's COPD treatment
AstraZeneca's drug candidate tozorakimab met the primary endpoint in the phase 3 Miranda study and showed a statistically significant reduction in moderate to severe exacerbations in COPD patients, according to a press release.
ANNONS
The effect was seen both in former smokers and in the broader patient group.
The treatment also showed a good safety profile, and the results will now be submitted to authorities. Tozorakimab is also being studied in other indications, including severe viral infections in the lower respiratory tract and asthma.
COPD (Chronic Obstructive Pulmonary Disease) is a serious, chronic disease primarily caused by smoking and means that the airways are inflamed and damaged, leading to shortness of breath and impaired lung function.